Summary
YM-12617, 5-[2-[[2-(o-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide HCl is structurally novel, an extremely potent and highly selective α1-adrenoceptor antagonist. An asymmetric center exists at the α-carbon atom in the phenethylamine portion of YM-12617, therefore two optical enantiomers exist. α-Adrenoceptor blocking properties and hypotensive activities of YM-12617 and its enantiomers have been compared in vitro and in vivo. 1. In the isolated rabbit aorta, R(−)- and S(+)-YM-12617 competitively antagonized phenylephrine-induced contraction with pA2 values of 9.95 and 7.69, respectively. Although R(−)- and S(+)-YM-12617 were also competitive antagonists toward UK-14,304 at prejunctional α2-adrenoceptors in the isolated guinea-pig ileum, the affinities of R(−)-YM-12617 (pA2 = 6.18) and S(+)-YM-12617 (pA2 = 5.64) for these receptors were 5,900 and 110 times lower than those displayed for postjunctional α1-adrenoceptors in the isolated rabbit aorta. 2. R(−)- and S(+)-YM-12617 displaced both 3H-prazosin and 3H-idazoxan binding to rat brain membranes; however, the affinities of the R(−)- and S(+)-enantiomers for α1-adrenoceptors (pKi = 9.95 and 7.83, respectively) were 21,000 and 72 times higher than those for α2-adrenoceptors (pK i = 5.62 and 5.97), respectively. 3. Based on pA2 values obtained in the isolated tissues and pK i values in the binding assays, R(−)-YM-12617 was 132–182 times more potent than S(+)-YM-12617 as an antagonist at α1-adrenoceptors. In contrast, the R(−)- and S(+)-enantiomers were similar in potency at blocking α2-adrenoceptors. 4. In normotensive pithed rats, R(−)- and S(+)-YM-12617 preferentially antagonized the α1-adrenoceptor mediated pressor effect of phenylephrine with DR10 values of 1.38 and 705 μg/kg i. v., respectively, although a high dose (3,000 μg/kg i.v.) also inhibited the effect of UK-14,304 at postjunctional α2-adrenoceptors. R(−)-YM-12617 exhibited an over 2,000-fold selectivity for postjunctional α1-adrenoceptors, and R(−)-YM-12617 was over 500 times more potent than S(+)-YM-12617 in antagonizing postjunctional α1-adrenoceptors based on DR10 values. 5. In anesthetized rats, R(−)- and S(+)-YM-12617 dose-dependently produced hypotension with ED20 values, doses required decreased mean blood pressure by 20%, of 0.64 and 61 μg/kg i. v., respectively. R(−)-YM-12617 exerted a 95 times more potent hypotensive activity than S(+)-YM-12617, and its isomeric activity ratio was consistent with that for α1-adrenoceptors but not α2-adrenoceptors. 6. The present results suggest that the high stereoselectivity of the optical enantiomers of YM-12617 is in the α1-adrenoceptor, but not in the α2-adrenoceptor, and their antagonist potency for α1-adrenoceptors is likely to contribute to the hypotensive effect.
Similar content being viewed by others
References
Arunlakshana O, Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14: 48–58
Berthelsen S, Pettinger WA (1977) A functional basis for classification of alpha-adrenergic receptors. Life Sci 21:595–606
Brittain RT, Drew GM, Levy GP (1982) The α- and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs in isolated tissues. Br J Pharmacol 77:105–114
Cambridge D (1981) UK-14,304, a potent and selective α2-agonist for the characterisation of α-adrenoceptor subtypes. Eur J Pharmacol 72:413–415
Cheng HC, Reavis OK Jr, Grisar JM, Claxton GP, Weiner DL, Woodward JK (1980) Antihypertensive and adrenergic receptor blocking properties of the enantiomers of medroxalol. Life Sci 27:2529–2534
Delean A, Munson PJ, Rodbard D (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235: E97-E102
Docherty JR, Starke K (1981) Postsynaptic alpha-adrenoceptor subtype in rabbit blood vessels and rat anococcygeus muscle studied in vitro. J Cardiovasc Pharmacol 3:854–866
Doxey JC, Roach AG, Smith CFC (1983) Studies on RX 781094: a selective, potent and specific antagonist of α2-adrenoceptors. Br J Pharmacol 78:489–505
Doxey JC, Lane AC, Roach AG, Virdee NK (1984a) Comparison of the α-adrenoceptor antagonist profiles of idazoxan (RX781094), yohimbine, rauwolscine and corynanthine. Naunyn-Schmiedeberg's Arch Pharmacol 325:136–144
Doxey JC, Roach AG, Strachan DA, Virdee NK (1984b) Selectivity and potency of 2-alkylanalogues of the α2-adrenoceptor antagonist idazoxan (RX781094) in peripheral systems. Br J Pharmacol 83: 713–722
Easson LH, Stedman E (1933) Studies on the relationship between chemical constitution and physiological action. V. Molecular dissymmetry and physiological activity. Biochem J 27:1257–1266
Fujii K, Kuriyama H (1985) Effects of YM-12617, an alpha adrenoceptor blocking agent, on electrical and mechanical properties of the guinea-pig mesenteric and pulmonary arteries. J Pharmacol Exp Ther 235:764–770
Furchgott RF (1972) The classification of adrenoceptors (adrenergic receptors). An evaluation from the standpoint of receptor theory. In: Blaschko H, Muscholl E (eds) Catecholamines. Springer, Berlin Heidelberg New York, pp 283–335
Honda K, Nakagawa C (1986) Alpha-1 adrenoceptor antagonist effects of the optical isomers of YM-12617 in rabbit lower urinary tract and prostate. J Pharmacol Exp Ther 239:512–516
Honda K, Takenaka T, Miyata-Osawa A, Terai M, Shiono K (1985a) Studies on YM-12617: A selective and potent antagonist of postsynaptic α1-adrenoceptors. Naunyn-Schmiedeberg's Arch Pharmacol 328:264–272
Honda K, Miyata-Osawa A, Takenaka T (1985b) α1-Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits. Naunyn-Schmiedeberg's Arch Pharmacol 330:16–21
Honda K, Takenaka T, Shiono K, Miyata-Osawa A, Nakagawa C (1985c) Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined α- and β-adrenoceptor blocking agent in conscious rats. Jpn J Pharmacol 38: 31–41
Honda K, Takenaka T, Miyata-Osawa A, Terai M (1986a) Adrenoceptor blocking properties of the stereoisomers of amosulalol (YM-09538) and the corresponding desoxy derivative (YM-11133). J Pharmacol Exp Pharmacol 236:776–783
Honda K, Nakagawa C, Inagaki O, Shibasaki M, Takenaka T, Takeda M (1986b) Adrenoceptor blocking and cardiovascular effects of the optical isomers of amosulalol (YM-09538), a combined α- and β-adrenoceptors blocking agent, and the corresponding desoxy derivative (YM-11133) in rats. Jpn J Pharmacol 41:459–466
Kapur H, Mottram DR (1978) A comparative study on the preand postsynaptic alpha blocking activity of a series of benzodioxanes. Biochem Pharmacol 27:1879–1880
Konno F, Takayanagi I (1986) Characterization of postsynaptic alpha1 -adrenoceptors in the rabbit iris dilator smooth muscle. Naunyn-Schmiedeberg's Arch Pharmacol 333:271–276
Lands AM, Arnold A, McAuliff JP, Luduena FP, Brown TG Jr (1967) Differentiation of receptor systems activated by sympathomimetic amines. Nature (Lond) 214:597–598
Langer SZ (1974) Presynaptic regulation of catecholamine release. Biochem Pharmacol 23:1793–1800
McGrath JC (1982) Evidence for more than one type of post-junctional α-adrenoceptor. Biochem Pharmacol 31:467–484
Patil PN, Miller DD, Trendelenburg U (1974) Molecular geometry and adrenergic drug activity. Pharmacol Rev 26: 323–392
Paton WDM, Zar A (1969) The origin of acetylcholine released from guinea-pig intestine and longitudinal muscle strips. J Physiol 194:13–33
Ruffolo RR Jr, Wadell JE (1982) Stereochemical requirements of α2-adrenergic receptors for α-methyl substituted phenethylamines. Life Sci 31:2999–3007
Ruffolo RR Jr, Rice PJ, Patil PN, Hamada A, Miller DD (1983a) Differences in the applicability of the Easson-Stedman Hypothesis to α1- and α2-adrenergic effects of phenethylamines and imidazolines. Eur J Pharmacol 86:471–475
Ruffolo RR Jr, Banning JW, Patil PN, Hamada A, Miller DD (1983b) Evaluation of the adrenergic effects of a novel optically active catecholamidine in vitro and in vivo: Differential application of the Easson-Stedman Hypothesis to alpha and beta adrenoceptors. J Pharmacol Exp Ther 226:469–477
Ruffolo RR Jr (1984) Use of isolated, physiologically responding tissues to investigate neurotransmitter receptors. In: Cohen MM (ed) Monogr Neural Sci, vol 10. Karger, Basel, pp 53–84
Starke K (1981) α-Adrenoceptor subclassification. Rev Physiol Biochem Pharmacol 88:199–236
Starke K, Langer SZ (1979) A note on terminology for presynaptic receptors. In: Langer SZ, Starke K, Dubocovich ML (eds) Advances in the biosciences, vol 18, Presynaptic receptors. Pergamon Press, New York, pp 1–3
Takayanagi I, Konno F, Kameda H, Kubo H, Furukawa A, Toyoda T (1986) A difference in mode of antagonism between optical isomers of a potent selective alpha s-adrenoceptor blocker (YM-12617) and norepinephrine in isolated rabbit iris dilator and aorta. Jpn J Pharmacol 42:579–582
Takenaka T, Honda K, Fujikura T, Niigata K, Tachikawa S, Inukai N (1984) New sulfamoylphenethylamines, potent α1-adrenoceptor antagonists. J Pharm Pharmacol 30: 539–542
Terai M, Takenaka T, Maeno H (1983) Measurements of pharmacological and 3H-ligand binding in adrenergic receptors. In: Parvez S, Nagatsu T, Nagatsu I, Parvez H (eds) Methods in biogenic amine research. Elsevier/Science Publishers, Amsterdam New York, pp 574–590
U'Prichard DC, Greenberg DA, Snyder SH (1977) Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha-noradrenergic receptors. Mol Pharmacol 13:454–473
van Meel JCA, de Jonge A, Timmermans PBMWM, van Zwieten PA (1981) Selectivity of some alpha adrenoceptor agonists for peripheral alpha-1 and alpha-2 adrenoceptors in the normotensive rat. J Pharmacol Exp Ther 219:760–767
van Rossum JM (1963) Cumulative dose-response curves. II. Technique for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch Int Pharmacodyn 143:299–330
Wikberg JES (1978) Pharmacological classification of adrenergic alpha-receptors in the guinea pig. Nature (Lond) 273:164–166
Yamada S, Ushijima H, Ashizawa N, Nakayama K, Hayashi E, Honda K (1987) Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy. J Pharmacol Exp Ther 242 (in press)
Author information
Authors and Affiliations
Additional information
Send offprint requests to K. Honda
Rights and permissions
About this article
Cite this article
Honda, K., Nakagawa, C. & Terai, M. Further studies on (±)-YM-12617, a potent and selective α1-adrenoceptor antagonist and its individual optical enantiomers. Naunyn-Schmiedeberg's Arch Pharmacol 336, 295–302 (1987). https://doi.org/10.1007/BF00172681
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00172681